{"id":10320,"date":"2026-09-23T06:37:30","date_gmt":"2026-09-23T11:37:30","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=10320"},"modified":"2026-09-23T06:44:02","modified_gmt":"2026-09-23T11:44:02","slug":"nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","title":{"rendered":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"10320\" class=\"elementor elementor-10320\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6d5ad04f elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"6d5ad04f\" data-element_type=\"section\" data-e-type=\"section\">\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5bf9bdef\" data-id=\"5bf9bdef\" data-element_type=\"column\" data-e-type=\"column\">\r\n\r\n\t\t\t\t\r\n\t\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-e3a8c93 elementor-widget-tablet__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"e3a8c93\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul type=\"disc\"><li><i>Jordi Mones, MD, PhD, to present the first direct-to-Phase 2 randomized, controlled trial data on sonpiretigene isteparvovec optogenetic therapy in macular degeneration<\/i><\/li><li><i>Benjamin Bakall, MD, PhD, to present 4-year REMAIN extension study data on lasting vision improvement with MCO-010 in retinitis pigmentosa<\/i><\/li><li><i>Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer, to deliver a company presentation at the Retina Forum 2026 in Ophthalmology Futures Forums<\/i><\/li><li><i>Samuel Barone, MD, Chief Medical Officer, to participate in a panel on GA and Intermediate AMD at the Retina Forum 2026 in Ophthalmology Futures Forums<\/i><\/li><\/ul><p><span class=\"legendSpanClass\">DALLAS<\/span>,\u00a0<span class=\"legendSpanClass\">Sept. 23, 2026<\/span>\u00a0 \u2014 <a href=\"http:\/\/nanostherapeutics.com\/es\/\" target=\"_blank\" rel=\"nofollow noopener\">Terap\u00e9utica del nanoscopio<\/a>, Inc., a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that Jordi Mones, MD, PhD, and Benjamin Bakall, MD, PhD, will present data from Nanoscope&#8217;s geographic atrophies and retinitis pigmentosa programs at the\u00a0<a href=\"https:\/\/euretina.org\/vienna-2026\/\" target=\"_blank\" rel=\"nofollow noopener\"><b>26<\/b><b><sup>th<\/sup><\/b><b>\u00a0Congreso Europeo<\/b><\/a><b>, taking place October 1-4, 2026, at the VIECON \u2013 Vienna Congress &amp; Convention Center in Vienna.<\/b>\u00a0The Company also announced that Samarendra Mohanty, Co-Founder, President, and Chief Scientific Officer, and Samuel Barone, the Chief Medical Officer, will deliver a company presentation at the\u00a0<a href=\"https:\/\/www.ophthalmology-futures.com\/retina-forum-2026\/\" target=\"_blank\" rel=\"nofollow noopener\"><b>Retina Forum 2026<\/b><\/a><b>,\u00a0<\/b>\u00a0<b>in the Ophthalmology Futures Forums taking place September 30, 2026,in Vienna.<\/b><\/p><p><b>Detalles de la presentaci\u00f3n:<\/b><\/p><p><a href=\"https:\/\/www.ophthalmology-futures.com\/retina-forum-2026\/\" target=\"_blank\" rel=\"nofollow noopener\"><b>Ophthalmology Futures Forums \u2013 Retina Forum 2026<\/b><\/a><br class=\"dnr\" \/><b>Company Presentation<br class=\"dnr\" \/><\/b><b>Presentador:\u00a0<\/b>Samarendra Mohanty, PhD, Co-Founder, President, and Chief Scientific Officer<br class=\"dnr\" \/><b>Fecha y hora:\u00a0<\/b>Wednesday, September 30, 2026, 17:50 PM CEST<br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b><a href=\"https:\/\/www.imperialridingschool.com\/en\" target=\"_blank\" rel=\"nofollow noopener\">Imperial Riding School<\/a>, Vienna<\/p><p><b>Panel 8:\u00a0<\/b><i>Geographic Atrophy &amp; Intermediate AMD Therapeutics: Regional Evolution of a Global Business<br class=\"dnr\" \/><\/i><b>Miembro del jurado:\u00a0<\/b>Samuel Barone, MD, director m\u00e9dico<br class=\"dnr\" \/><b>Fecha y hora:\u00a0<\/b>Wednesday, September 30, 2026, 18:20 PM CEST<br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b><a href=\"https:\/\/www.imperialridingschool.com\/en\" target=\"_blank\" rel=\"nofollow noopener\">Imperial Riding School<\/a>, Vienna<\/p><p><a href=\"https:\/\/euretina.org\/vienna-2026\/\" target=\"_blank\" rel=\"nofollow noopener\"><b>26<\/b><b><sup>th<\/sup><\/b><b>\u00a0Congreso Europeo<\/b><\/a><br class=\"dnr\" \/><b>T\u00edtulo de presentaci\u00f3n:\u00a0<\/b><i>Vision Improvement in Macular Degeneration with Sonpiretigene Isteparvovec Optogenetic Therapy: First Direct-to-Phase 2 Randomized, Controlled Trial<br class=\"dnr\" \/><\/i><b>Presentador:\u00a0<\/b>Jordi Mones, MD, PhD, Director, Institut de la M\u00e0cula, Barcelona, and member of the Nanoscope Visionary Advisory Committee<br class=\"dnr\" \/><b>Fecha y hora:\u00a0<\/b>Sunday, October 4, 2026, 10:51 AM CEST<br class=\"dnr\" \/><b>Sesi\u00f3n:\u00a0<\/b>Free Paper 42 \u2013 AMD\/CSC<br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b>Free Paper Forum 1<\/p><p><b>Poster Presentation:\u00a0<\/b><i>Optogenetic REMAIN 4-Year Study Data: Lasting Vision Improvement with MCO-010 in the RESTORE Phase 2b\/3 Trial for Retinitis Pigmentosa<br class=\"dnr\" \/><\/i><b>Presentador:\u00a0<\/b>Benjamin Bakall, MD, PhD, -Director for Clinical Research, Associated Retina Consultants, Phoenix, Arizona, and Assistant Professor, University of Arizona College of Medicine, Phoenix, Arizona<br class=\"dnr\" \/><b>Fecha:\u00a0<\/b>Thursday, October 1, 2026<br class=\"dnr\" \/><b>Sesi\u00f3n:\u00a0<\/b>Inherited Retinal Diseases ePosters (RETINA26-1615)<br class=\"dnr\" \/><b>Ubicaci\u00f3n:\u00a0<\/b>Poster Hub<\/p><p>These presentations, together with the Company&#8217;s corporate update on\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">FDA acceptance of the BLA for MOGENRY\u00ae\u00a0<\/a>\u00a0at the Ophthalmology Futures Forums Retina Forum, highlight the breadth of Nanoscope&#8217;s optogenetic pipeline, spanning the first direct-to-Phase 2 randomized, controlled trial of sonpiretigene isteparvovec in macular degeneration, and continued 4-year durability data from the RESTORE Phase 2b\/3 trial in retinitis pigmentosa.<\/p><p><b>Acerca de MOGENRY\u00ae (sonpiretigene isteparvovec; MCO-010)<br class=\"dnr\" \/><\/b>La tecnolog\u00eda de opsina multicaracter\u00edstica (MCO) de Nanoscope utiliza una opsina sint\u00e9tica patentada, modificada gen\u00e9ticamente, para optimizar su rendimiento en t\u00e9rminos de alta sensibilidad a la luz en un amplio espectro y una cin\u00e9tica r\u00e1pida. Tras la concepci\u00f3n e invenci\u00f3n de la tecnolog\u00eda por parte de Samarendra Mohanty, cofundador, presidente y director cient\u00edfico de Nanoscope, su equipo ha dedicado m\u00e1s de una d\u00e9cada a evaluar su rendimiento en diversos modelos animales y enfermedades humanas. MOGENRY\u00ae es una terapia g\u00e9nica optogen\u00e9tica intrav\u00edtrea experimental, de una sola aplicaci\u00f3n y administrada en consulta, basada en la plataforma MCO de Nanoscope. Al administrar un gen de opsina multicaracter\u00edstica a las c\u00e9lulas bipolares de la retina, de alta densidad, MOGENRY\u00ae confiere a estas c\u00e9lulas supervivientes sensibilidad directa a la luz, permiti\u00e9ndoles utilizar el circuito visual restante tras la p\u00e9rdida de fotorreceptores. MOGENRY\u00ae no requiere pruebas gen\u00e9ticas, cirug\u00eda invasiva ni dosis repetidas, y est\u00e1 dise\u00f1ado para su administraci\u00f3n dentro de los flujos de trabajo habituales en las consultas de retina.<\/p><p><b>Acerca de Nanoscope Therapeutics<br class=\"dnr\" \/><\/b>Nanoscope Therapeutics est\u00e1 desarrollando una terapia optogen\u00e9tica restauradora de la visi\u00f3n, independiente de la enfermedad, para millones de pacientes ciegos por enfermedades degenerativas de la retina. Tras los resultados positivos del ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo RESTORE Fase 2b\/3 para la retinosis pigmentaria (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04945772\" target=\"_blank\" rel=\"nofollow noopener\">NCT04945772<\/a>), el\u00a0<a href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/09\/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss\/\" target=\"_blank\" rel=\"nofollow noopener\">La FDA ha aceptado y presentado la solicitud de licencia biol\u00f3gica (BLA) de la compa\u00f1\u00eda para MOGENRY\u00ae.<\/a>. Si se aprueba, MOGENRY\u00ae tiene el potencial de convertirse en el tratamiento est\u00e1ndar para pacientes con RP, administrado como una inyecci\u00f3n \u00fanica en el consultorio sin necesidad de pruebas gen\u00e9ticas. La compa\u00f1\u00eda tambi\u00e9n ha mostrado resultados prometedores en el ensayo cl\u00ednico de fase 2 STARLIGHT de MCO-010 en la enfermedad de Stargardt (SD) (<a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05417126\" target=\"_blank\" rel=\"nofollow noopener\">NCT05417126<\/a>) y planea iniciar un ensayo de registro de Fase 3 en 2026. MCO-010 ha recibido las designaciones de V\u00eda R\u00e1pida y Medicamento Hu\u00e9rfano de la FDA para RP y SD, junto con la designaci\u00f3n RMAT para SD, y las designaciones de Medicamento Hu\u00e9rfano de la EMA que cubren distrofias dominantes de bastones y conos no sindr\u00f3micas y sindr\u00f3micas, as\u00ed como distrofias maculares. MCO-010 tambi\u00e9n ha recibido las designaciones de Sakigake y Medicamento Hu\u00e9rfano para distrofias retinianas hereditarias (IRD) en Jap\u00f3n y una designaci\u00f3n de Medicamento Hu\u00e9rfano para IRD en Arabia Saudita. Se espera que un programa de Fase 2 para MCO en atrofia geogr\u00e1fica comience en 2026, y otros programas listos para IND incluyen amaurosis cong\u00e9nita de Leber (LCA).<\/p><p><b>Contacto:<\/b><\/p><p>Nanoscope Therapeutics, Inc<br class=\"dnr\" \/>(817) 857-1186<br class=\"dnr\" \/><u><a href=\"mailto:PR@nanostherapeutics.com\" target=\"_blank\" rel=\"nofollow noopener\">PR@nanostherapeutics.com<\/a><\/u><\/p><p>FUENTE Terap\u00e9utica del Nanoscopio<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>Jordi Mones, MD, PhD, to present the first direct-to-Phase 2 randomized, controlled trial data on sonpiretigene isteparvovec optogenetic therapy in macular degeneration Benjamin Bakall, MD, PhD, to present 4-year REMAIN extension study data on lasting vision improvement with MCO-010 in retinitis pigmentosa Samarendra Mohanty, PhD, Co-Founder, President and Chief Scientific Officer, to deliver a company [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":10321,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-10320","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-23T11:37:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-23T11:44:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Wilson PJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Wilson PJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\"},\"author\":{\"name\":\"Wilson PJ\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\"},\"headline\":\"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum\",\"datePublished\":\"2026-09-23T11:37:30+00:00\",\"dateModified\":\"2026-09-23T11:44:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\"},\"wordCount\":793,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_Euretina26_Thumb.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\",\"name\":\"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_Euretina26_Thumb.jpg\",\"datePublished\":\"2026-09-23T11:37:30+00:00\",\"dateModified\":\"2026-09-23T11:44:02+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_Euretina26_Thumb.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/NSCOPE_Euretina26_Thumb.jpg\",\"width\":823,\"height\":819},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2026\\\/09\\\/23\\\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/2fa4c7d9fcf90c2c01f1341935baf02d\",\"name\":\"Wilson PJ\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2026-09-23T11:37:30+00:00","article_modified_time":"2026-09-23T11:44:02+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Wilson PJ","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Wilson PJ","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/"},"author":{"name":"Wilson PJ","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d"},"headline":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum","datePublished":"2026-09-23T11:37:30+00:00","dateModified":"2026-09-23T11:44:02+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/"},"wordCount":793,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_Euretina26_Thumb.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","url":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/","name":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_Euretina26_Thumb.jpg","datePublished":"2026-09-23T11:37:30+00:00","dateModified":"2026-09-23T11:44:02+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_Euretina26_Thumb.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/NSCOPE_Euretina26_Thumb.jpg","width":823,"height":819},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2026\/09\/23\/nanoscope-therapeutics-to-present-macular-degeneration-and-retinitis-pigmentosa-data-at-the-26th-euretina-congress-and-ophthalmology-futures-forums-retina-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present Macular Degeneration and Retinitis Pigmentosa Data at the 26th Euretina Congress and Ophthalmology Futures Forums Retina Forum"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/2fa4c7d9fcf90c2c01f1341935baf02d","name":"Wilson P.J."}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10320","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=10320"}],"version-history":[{"count":6,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10320\/revisions"}],"predecessor-version":[{"id":10327,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/10320\/revisions\/10327"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/10321"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=10320"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=10320"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=10320"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}